Someit Sidhu
Gründer bei ZURA BIO LIMITED
Vermögen: 41 Mio $ am 30.04.2024
Ursprung des Netzwerks ersten Grades von Someit Sidhu
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Public Company | Biotechnology | 21 | |
Pathios Therapeutics Ltd.
Pathios Therapeutics Ltd. BiotechnologyHealth Technology Pathios Therapeutics Ltd. engages in discovering and developing novel small molecule drugs. The company was founded by Thomas David McCarthy, Alan Naylor, Kirsty McCarthy, Peter Joyce and Someit Sidhu in 2017 and is headquartered in Oxford, the United Kingdom.
4
| Holding Company | Biotechnology | 4 |
Izana Bioscience Ltd.
Izana Bioscience Ltd. BiotechnologyHealth Technology Part of Roivant Sciences Ltd., Izana Bioscience Ltd. is a British biotech company. The company is based in London, UK. The company's website, izanabio.com, provides general information about the company. The company was founded in 2017 by Someit Sidhu. Someit Sidhu has been the CEO since 2017.
3
| Subsidiary | Biotechnology | 3 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Someit Sidhu
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer Comptroller/Controller/Auditor Corporate Officer/Principal Director/Board Member | |
INCYTE CORPORATION | Pharmaceuticals: Major | Corporate Officer/Principal | |
MedImmune LLC
MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Biotechnology | Corporate Officer/Principal | |
REGENERON PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Boehringer Ingelheim GmbH
Boehringer Ingelheim GmbH Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim GmbH engages in the provision of central management and other services for the group companies on behalf of C.H. Boehringer Sohn AG & Co. KG. The group specializes in the development, production, and distribution of pharmaceutical products. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany. | Pharmaceuticals: Major | Corporate Officer/Principal | |
D.E. Shaw & Co., Inc.
D.E. Shaw & Co., Inc. Investment ManagersFinance D.E. Shaw & Co., Inc. engages in the provision of investment advisory services. The firm offers services to pooled investment vehicles. The company was founded by David E. Shaw in 1988 and was headquartered in New York, NY. | Investment Managers | Corporate Officer/Principal | |
ARENA PHARMACEUTICALS | Pharmaceuticals: Major | Chief Executive Officer Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer Director/Board Member Director/Board Member Corporate Officer/Principal Human Resources Officer Compliance Officer | |
RADIUS HEALTH, INC. | Biotechnology | Director/Board Member | |
EUSA Pharma, Inc.
EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Lanark Master Issuer Plc
Lanark Master Issuer Plc Investment Trusts/Mutual FundsMiscellaneous Lanark Master Issuer Plc is a special purpose company, which engages in issuing asset-backed securities. Its principal objectives are to lend money and give credit, secured and unsecured; to borrow and raise money; and to grant security over its property for the performance of its obligations and the payment of money. The company was founded on July 5, 2007 and is headquartered in London, the United Kingdom. | Investment Trusts/Mutual Funds | Director/Board Member | |
Heta Funding Designated Activity Co.
Heta Funding Designated Activity Co. Investment ManagersFinance Part of Deutsche Bank AG, Heta Funding Designated Activity Co. is an Irish investment advice company. The company is based in Dublin, Ireland. Founded in 2009. | Investment Managers | Director/Board Member | |
Duke University
Duke University Other Consumer ServicesConsumer Services Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC. | College/University | Graduate Degree Graduate Degree | |
STARPHARMA HOLDINGS LIMITED | Pharmaceuticals: Major | Corporate Officer/Principal | |
University of Oxford | College/University | Graduate Degree | |
Monash University
Monash University Other Consumer ServicesConsumer Services Monash University operates as a public research university. It specializes in higher education, global engagement, postgraduate courses, undergraduate study, and PhD research. The company was founded on March 1961 and is headquartered in Clayton, Australia. | College/University | Undergraduate Degree | |
University of Messiah | College/University | Undergraduate Degree | |
State University of New York at Albany | College/University | Undergraduate Degree | |
Brandon Capital Partners Pty Ltd.
Brandon Capital Partners Pty Ltd. Investment ManagersFinance Brandon Capital Partners Pty Ltd. (Brandon Capital Partners) is a venture capital firm founded in 2007 by David Fisher and Chris Nave. The firm is headquartered in Sydney, Australia. | Investment Managers | Private Equity Investor Consultant / Advisor | |
SMART Reading /Oregon/
SMART Reading /Oregon/ Miscellaneous Commercial ServicesCommercial Services SMART Reading offers literacy support to children. It helps kids become confident readers by providing individual volunteer attention and new, take-home books. The company was founded in 1992 and is headquartered in Portland, OR. | Miscellaneous Commercial Services | Director/Board Member | |
Daiichi Sankyo, Inc.
Daiichi Sankyo, Inc. Pharmaceuticals: MajorHealth Technology Daiichi Sankyo, Inc. manufactures and supplies pharmaceutical products. It markets therapies in hypertension, dyslipidemia, diabetes, thrombosis, stroke risk reduction, acute coronary syndrome, opioid-induced constipation, IV iron therapy and metastatic melanoma. The company was founded in 2006 and is headquartered in Basking Ridge, NJ. | Pharmaceuticals: Major | Sales & Marketing | |
Blssp PHC 27 Ltd.
Blssp PHC 27 Ltd. Real Estate Investment TrustsFinance Part of BL Sainsbury Superstores Ltd., Blssp PHC 27 Ltd. provides property investment services. The company is based in London, UK. | Real Estate Investment Trusts | Director/Board Member | |
BLSSP (PHC 30) Ltd.
BLSSP (PHC 30) Ltd. Real Estate Investment TrustsFinance Part of BL Sainsbury Superstores Ltd., BLSSP (PHC 30) Ltd. provides property investment services. The company is based in London, UK and was founded in 2000. | Real Estate Investment Trusts | Director/Board Member | |
Lanark Funding Ltd.
Lanark Funding Ltd. Finance/Rental/LeasingFinance Part of Virgin Money UK Plc, Lanark Funding Ltd. is a company that provides financial intermediary services. The company is based in London, UK. | Finance/Rental/Leasing | Director/Board Member | |
InCarda Therapeutics, Inc.
InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | Biotechnology | Chief Executive Officer | |
Graduate School of Business | College/University | Masters Business Admin | |
Harvard College | College/University | Undergraduate Degree Undergraduate Degree | |
Lanark Trustees Ltd.
Lanark Trustees Ltd. Financial ConglomeratesFinance Part of Virgin Money UK Plc, Lanark Trustees Ltd. provides investment services. The company is based in London, UK. | Financial Conglomerates | Director/Board Member | |
PULMATRIX, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
West Virginia University School of Medicine | College/University | Doctorate Degree | |
P2PCL 1 PLC
P2PCL 1 PLC Financial ConglomeratesFinance Part of Castlewood CS Holdings Ltd., P2PCL 1 PLC is a British financial intermediary company founded in 2014. The company provides financial intermediation services and is based in London, UK. | Financial Conglomerates | Director/Board Member | |
Orbit Discovery Ltd.
Orbit Discovery Ltd. Pharmaceuticals: MajorHealth Technology Orbit Discovery Ltd. develops technology for discovery process and drug development. The company was founded by Terry Rabbitts and Graham Ogg and is headquartered in Oxford, the United Kingdom. | Pharmaceuticals: Major | Chairman | |
LifeMine Therapeutics, Inc.
LifeMine Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology LifeMine Therapeutics, Inc. develops drugs from fungi which aims to cure untreatable and significant chronic diseases. The company was founded by Gregory L. Verdine, WeiQing Zhou, Richard D. Klausner and Hingge Hsu and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
Athanor Capital LP
Athanor Capital LP Investment ManagersFinance Athanor Capital LP (Athanor) is a hedge fund manager headquartered in New York City. The firm was founded by Parvinder S. Thiara in 2017 and is a subsidiary of Athanor Capital GP LLC. Athanor serves as the investment adviser, with discretionary trading authority over private pooled investment vehicles. | Investment Managers | Founder | |
Grey Wolf Therapeutics Ltd.
Grey Wolf Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Grey Wolf Therapeutics Ltd. is a biotechnology company, which engages in the drug discovery in immuno-oncology. It targets endoplasmic reticulum aminopeptidases 1 and 2 in the antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells. The company was founded by Thomas D. McCarthy and Peter Joyce and is headquartered in Oxford, the United Kingdom. | Pharmaceuticals: Major | Founder Founder Chief Operating Officer | |
New Skye (UK) Ltd.
New Skye (UK) Ltd. Finance/Rental/LeasingFinance New Skye (UK) Ltd. was founded in 2009 and functions as a financing subsidiary/special purpose entity. The private company is based in London, UK. | Finance/Rental/Leasing | Director/Board Member | |
DERMTECH, INC. | Medical Specialties | Chief Tech/Sci/R&D Officer | |
University of Liverpool Management School | College/University | Graduate Degree | |
Sapphire Aviation Finance I (UK) Ltd.
Sapphire Aviation Finance I (UK) Ltd. Finance/Rental/LeasingFinance Part of Massachusetts Mutual Life Insurance Co., Sapphire Aviation Finance I (UK) Ltd. is a British company that leases aircraft. The company is based in London, UK. Sapphire Aviation Finance I (UK was founded in 2018. | Finance/Rental/Leasing | Director/Board Member | |
Adiso Therapeutics, Inc.
Adiso Therapeutics, Inc. BiotechnologyHealth Technology Adiso Therapeutics, Inc. creates medicines to treat inflammatory diseases with the goal of improving the lives of patients and their families. Adiso Therapeutics is based in Concord, MA. The company believes that current therapeutic approaches are often inadequate and can pose significant safety concerns for patients. Scott T. Megaffin has been the CEO of the company since 2022. | Biotechnology | Director/Board Member | |
CADRENAL THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Tourmaline Bio, Inc.
Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | Miscellaneous Commercial Services | Founder Director/Board Member | |
Uber, Inc.
Uber, Inc. Specialty StoresRetail Trade UBER, Inc. retails outdoor sports products. The company was founded on February 2, 2007 and is headquartered in Fountain Valley, CA. | Specialty Stores | Corporate Officer/Principal | |
METACRINE, INC. | Biotechnology | Chief Executive Officer Human Resources Officer |
Statistik
International
Vereinigte Staaten | 28 |
Vereinigtes Königreich | 14 |
Australien | 4 |
Deutschland | 2 |
Irland | 2 |
Sektoral
Health Technology | 22 |
Finance | 14 |
Consumer Services | 10 |
Commercial Services | 3 |
Miscellaneous | 2 |
Operativ
Director/Board Member | 78 |
Corporate Officer/Principal | 47 |
Independent Dir/Board Member | 27 |
Chief Tech/Sci/R&D Officer | 26 |
Founder | 20 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Amit Munshi | 26 |
Timothy Corn | 20 |
Jennifer Jarrett | 18 |
Christopher Cabell | 16 |
Preston Klassen | 15 |
Neil Graham | 14 |
Steven Schoch | 11 |
Sandeep Kulkarni | 11 |
Michael Howell | 10 |
Sunil Masson | 10 |
Robert Lisicki | 9 |
Theresa Lowry | 9 |
Kimberly Ann Davis | 7 |
Thomas Mccarthy | 7 |
Parvinder Thiara | 7 |
- Börse
- Insiders
- Someit Sidhu
- Unternehmensverbindungen